Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates

Prostate

Volumn 72, Issue 3, 2012, Pages 318-325

  Beer, Marc ^a   Montani, Matteo ^b   Gerhardt, Josefine ^a   Wild, Peter J ^a   Hany, Thomas F ^a   Hermanns, Thomas ^a   Müntener, Michael ^a   Kristiansen, Glen ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

androgen receptor; bombesin; cyclin d1; immunohistochemistry; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CYCLIN D1; GASTRIN RELEASING PEPTIDE;

ADULT; AGED; ARTICLE; CARCINOMA; CASTRATION; COHORT ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CASTRATION; CYCLIN D1; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, BOMBESIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84855701740     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21434     Document Type: Article

References (38)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46 (4): 765-781.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin 2007; 57 (1): 43-66. (Pubitemid 46148091)
3. Horwich A, Parker C, Kataja V,. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 76-78.
4. Weissbach L, Altwein J,. Active surveillance or active treatment in localized prostate cancer? Dtsch Arztebl Int 2009; 106 (22): 371-376.
5. Djavan B, Eckersberger E, Finkelstein J, Sadri H, Taneja SS, Lepor H,. Prostate-specific antigen testing and prostate cancer screening. Prim Care 2010; 37 (3): 441-459, vii.
6. Bangma CH, Roobol MJ, Steyerberg EW,. Predictive models in diagnosing indolent cancer. Cancer 2009; 115 (13 Suppl.): 3100-3106.
7. Armstrong AJ, Febbo PG,. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: An update and review of the literature. Oncologist 2009; 14 (8): 816-827.
8. Spindel ER, Giladi E, Brehm P, Goodman RH, Segerson TP,. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol 1990; 4 (12): 1956-1963.
9. Jensen RT, Battey JF, Spindel ER, Benya RV,. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: Nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008; 60 (1): 1-42. (Pubitemid 351439216)
10. Hohla F, Schally AV,. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle 2010; 9 (9): 1738-1741.
11. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M,. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 2005; 64 (3): 303-315. (Pubitemid 40980872)
12. Cornelio DB, Roesler R, Schwartsmann G,. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007; 18 (9): 1457-1466. (Pubitemid 47365477)
13. Patel O, Shulkes A, Baldwin GS,. Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006; 1766 (1): 23-41. (Pubitemid 44175629)
14. Levine L, Lucci JA III, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Jr, Hellmich MR,. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63 (13): 3495-3502. (Pubitemid 36793027)
15. Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstadter F, Hartmann A, Jaggi R, Moch H, Kristiansen G, Wild PJ,. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2011; 17 (5): 1111-1121.
16. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Muntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezavi A, Wild P, Hofstadter F, Burger M, Moch H, Kristiansen G,. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer 2010; 10: 341.
17. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE,. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 2011; 52 (3): 470-477.
18. Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S,. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011; 52 (2): 270-278.
19. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR,. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011; 38 (1): 97-107.
20. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ,. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem 2003; 14 (4): 756-763. (Pubitemid 36875435)
21. Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR,. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTAPESIN). Cancer Res 2011; 71 (3): 1009-1018.
22. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M,. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods: 2009; 48 (2): 200-204.
23. Sancho V, Di Florio A, Moody TW, Jensen RT,. Bombesin receptor mediated imaging and cytotoxicity: Review and current status. Curr Drug Deliv 2011; 8 (1): 79-134.
24. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV,. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 1999; 276 (3 Pt 1): G655-G665. (Pubitemid 29157431)
25. Rivera CA, Ahlberg NC, Taglia L, Kumar M, Blunier A, Benya RV,. Expression of GRP and its receptor is associated with improved survival in patients with colon cancer. Clin Exp Metastasis 2009; 26 (7): 663-671.
26. Cornelio DB, Meurer L, Roesler R, Schwartsmann G,. Gastrin-releasing peptide receptor expression in cervical cancer. Oncology 2007; 73 (5-6): 340-345. (Pubitemid 351862026)
27. Van de Wiele C, Phonteyne P, Pauwels P, Goethals I, Van den Broecke R, Cocquyt V, Dierckx RA,. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med 2008; 49 (2): 260-264. (Pubitemid 351225665)
28. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ,. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009; 69 (10): 1101-1108.
29. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H,. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: Implications for tissue-based diagnostics. Br J Cancer 2008; 99 (6): 939-948.
30. Tischler V, Fritzsche FR, Gerhardt J, Jager C, Stephan C, Jung K, Dietel M, Moch H, Kristiansen G,. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. Histopathology 2010; 56 (6): 811-815.
31. Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M,. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer 2010; 126 (12): 2826-2834.
32. Folkerd EJ, Dowsett M,. Influence of sex hormones on cancer progression. J Clin Oncol 2010; 28 (26): 4038-4044.
33. Kung HJ, Evans CP,. Oncogenic activation of androgen receptor. Urol Oncol 2009; 27 (1): 48-52.
34. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA,. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006; 175 (4): 1337-1340.
35. Xiao D, Chinnappan D, Pestell R, Albanese C, Weber HC,. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res 2005; 65 (21): 9934-9942. (Pubitemid 41541474)
36. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE,. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res 2003; 63 (16): 4903-4913. (Pubitemid 37022625)
37. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG,. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP associated factor (P/CAF)-dependent manner. Mol Endocrinol 2001; 15 (5): 797-811. (Pubitemid 32411317)
38. Comstock CE, Augello MA, Schiewer MJ, Karch J, Burd CJ, Ertel A, Knudsen ES, Jessen WJ, Aronow BJ, Knudsen KE,. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem 2011; 286 (10): 8117-8127.